- Home
- ANIX vs TTRX Comparison
ANIX vs TTRX Comparison
Compare ANIX & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ANIX | TTRX |
|---|---|---|
| Founded | 1982 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 104.0M | 116.0M |
| IPO Year | 1987 | N/A |
Fundamental Metrics
Financial Performance| Metric | ANIX | TTRX |
|---|---|---|
| Price | $2.99 | $3.90 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | ★ $9.00 | $8.00 |
| AVG Volume (30 Days) | ★ 244.6K | 41.8K |
| Earning Date | 03-10-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.33 | $2.57 |
| 52 Week High | $5.46 | $26.50 |
Technical Indicators
Market Signals| Indicator | ANIX | TTRX |
|---|---|---|
| Relative Strength Index (RSI) | 34.76 | N/A |
| Support Level | $2.75 | N/A |
| Resistance Level | $3.09 | N/A |
| Average True Range (ATR) | 0.15 | 0.00 |
| MACD | -0.01 | 0.00 |
| Stochastic Oscillator | 5.00 | 0.00 |
Price Performance
Historical ComparisonAbout ANIX Anixa Biosciences Inc.
Anixa Biosciences Inc a cancer-focused biotechnology company, develops vaccines and therapies that are focused on critical unmet needs in oncology. The company is developing both diagnostics and therapeutics to detect cancer early, which is curable, and to treat those afflicted once diagnosed. Its segment includes CAR-T Therapeutics; Cancer Vaccines; Anti-Viral Therapeutics and others.
About TTRX Turn Therapeutics Inc.
Turn Therapeutics Inc is a clinical-stage biotechnology company focused on developing pharmaceutical and medical device products for dermatology, wound care, and infectious disease. The company's proprietary platform technology, called PermaFusion, enhances drug performance by improving the stability and bioavailability of active pharmaceutical ingredients, which allows for reduced doses and fewer side effects. Its primary development programs target skin conditions such as moderate to severe eczema and onychomycosis.